Most Read Articles
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist speaks to Cpt. Manvikram Singh Gill, military pharmacist with the Royal Medical and Dental Corps (RMDC) of the Malaysian Armed Forces (MAF),about his work at the Rohingya refugee camp in Cox's Bazar, Bangladesh.

Audrey Abella, 21 Sep 2020
A single-inhaler triple therapy containing FF/UMEC/VI* may be a good option for COPD** patients who remain symptomatic despite dual bronchodilation with an ICS/LABA or a LAMA/LABA*** and at risk for exacerbations, according to data presented at ERS 2020.

Weekly exenatide for type 2 diabetes delivers in real world

22 Nov 2020

Exenatide once weekly (EOW) provides effective glucose control and weight loss in patients with type 2 diabetes mellitus (T2DM), and these benefits are sustained through 18 months of treatment, according to real-world data.

The analysis included 186 patients (mean age, 63.2 years; 46.2 percent male; diabetes duration, 10.7 years) treated with EOW 2 mg in a real-world setting. These patients attended follow-up visits at 6, 12, and 18 months after treatment initiation.

After 6 months of treatment, HbA1c values dropped significantly (−0.9 percent, 95 percent confidence interval [CI], −1.1 to −0.8), as well as body weight (−2.8 kg, 95 percent CI, −3.4 to −2.2). More than half of the population (61 percent) achieved target HbA1c values of ≤7 percent, while 34 percent shed at least 5 percent of their baseline body weight at the 12-month follow up.

The reductions in blood sugar and weight were maintained at 18 months.

Shorter diabetes duration and nonuse of a different glucagon-like peptide-1 receptor agonist (GLP-1RA) predicted adequate glycaemic and weight response, respectively. Of note, patients on sulfonylureas failed to reach metabolic and body weight targets.

Gastrointestinal side effects (7.5 percent) and injection site reactions (6.4 percent) were the most common adverse events. A fraction of patients developed headache (1.1 percent) and allergic reactions (1.1 percent).

Treatment was discontinued in 79 patients (43 percent) because of insufficient HbA1c improvement and/or limited weight reduction (19.9 percent), side effects (16.1 percent), or patient decision (6.5 percent). Higher baseline HbA1c levels and use of basal insulin therapy prior to treatment initiation predicted EOW discontinuation.

The findings suggest that early initiation of EOW could improve glycaemic control and lower the risk of treatment discontinuation.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist speaks to Cpt. Manvikram Singh Gill, military pharmacist with the Royal Medical and Dental Corps (RMDC) of the Malaysian Armed Forces (MAF),about his work at the Rohingya refugee camp in Cox's Bazar, Bangladesh.

Audrey Abella, 21 Sep 2020
A single-inhaler triple therapy containing FF/UMEC/VI* may be a good option for COPD** patients who remain symptomatic despite dual bronchodilation with an ICS/LABA or a LAMA/LABA*** and at risk for exacerbations, according to data presented at ERS 2020.